Health · Pharma & Biotech · 2 hrs ago
South Korea’s Epe obesity drug set to reach some clinics Oct. 29
Hanmi Pharmaceutical developed Epe, a South Korean medicine for treating obesity.
Prescriptions are expected to begin at some medical centers on Oct.
29.
The rollout will happen in stages, depending on when each center receives the drug.
Wegovy, made by Novo Nordisk, and Mounjaro, made by Eli Lilly, have led the obesity-treatment market.
Epe is about 40% cheaper than Wegovy, according to the headline.
Its arrival is expected to intensify competition over prices and weight-loss results.
Hanmi Pharmaceutical’s obesity drug Epe is expected to begin being prescribed at some medical institutions in South Korea on Oct. 29.
The rollout is expected to proceed in stages according to when each institution receives the drug.
Epe will join a market led by Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.
The article headline says Epe is 40% cheaper than Wegovy.
- Who
- Hanmi Pharmaceutical, the developer of Epe, and medical institutions expected to prescribe it.
- What
- Epe, a South Korean obesity treatment, is expected to begin reaching some clinics.
- When
- Oct. 29, 2026.
- Where
- Some medical institutions in South Korea.
- Why
- The article says Epe is entering a market led by Wegovy and Mounjaro, bringing competition over price and weight-loss effects.
This story does not have two clearly opposing sides.
Chosun Ilbo reported that Epe was expected to begin being prescribed at some medical institutions on Oct. 29.
Prescribing of Epe is expected to begin at some medical institutions, with timing varying according to deliveries.
- Drug
- Epe
- Developer
- Hanmi Pharmaceutical
- Expected start
- Oct. 29, 2026
- Price comparison
- The headline says Epe is 40% cheaper than Wegovy
- Market competitors
- Wegovy and Mounjaro